missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ WIPI2 Polyclonal Antibody

Beschreibung
Positive Control: K562, THP-1, Jurkat Predicted Reactivity: Mouse (100%) Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
WD repeat proteins play a role in many essential biologic functions, regulating the assembly of multiprotein complexes by presenting a beta-propeller platform for simultaneous and reversible protein-protein interactions. WIPI2, also known as ATG18B or ATG21, is a human homolog to yeast ATG18 and contains three WD repeats and has a 7-bladed propeller structure with a conserved motif that facilitates its interaction with other proteins. It is recruited to early autophagosomal structures along with Atg16L and ULK1 and is required for the formation of LC3-positive autophagosomes. Along with the highly related WIPI1, WIPI2 is found at the plasma membrane in addition to autophagosomal membranes.
Spezifikation
Spezifikation
| Antigen | WIPI2 |
| Anwendungen | Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Klassifikation | Polyclonal |
| Konzentration | 0.57 mg/mL |
| Konjugat | Unconjugated |
| Zusammensetzung | PBS with 20% glycerol and 0.025% ProClin 300; pH 7 |
| Gen | WIPI2 |
| Gen-Zugriffsnummer | Q6AY57, Q9Y4P8 |
| Gen-Alias | 1110018O08Rik; 2510001I10Rik; ATG18B; Atg21; CGI-50; WD repeat domain phosphoinositide-interacting protein 2; WD repeat domain, phosphoinositide interacting 2; WD40 repeat protein interacting with phosphoinositides 2; WIPI2; WIPI-2; WIPI49-like protein 2 |
| Gensymbole | WIPI2 |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?